Transcode Therapeutics Stock Today
| RNAZ Stock | USD 10.25 0.38 3.85% |
PerformanceMild
| Odds Of DistressModerate
|
Transcode Therapeutics is trading at 10.25 as of the 4th of March 2026; that is 3.85 percent increase since the beginning of the trading day. The stock's open price was 9.87. Transcode Therapeutics has over 59 % chance of experiencing financial distress in the next 2 years of operation and did not have a very good performance during the last 90 trading days. The performance scores are derived for the period starting the 4th of December 2025 and ending today, the 4th of March 2026. Click here to learn more.
Business Domain Pharmaceuticals, Biotechnology & Life Sciences | IPO Date 8th of July 2021 | Category Healthcare | Classification Health Care |
TransCode Therapeutics, Inc., a biopharmaceutical company, engages in the development and commercialization of drugs and diagnostics for treating and identifying metastatic disease. The company was incorporated in 2016 and is based in Boston, Massachusetts. The company has 916.97 K outstanding shares of which 113.88 K shares are at this time shorted by private and institutional investors with about 0.21 trading days to cover. More on Transcode Therapeutics
Moving against Transcode Stock
Follow Valuation Profit Patterns Odds of Bankruptcy
Check how we calculate scores
Transcode Stock Highlights
ESG Sustainability
Environmental | Governance | Social |
| President, CFO | Thomas MBA | |||||||||||||||||||||||||||||||||||||||||||||
| Business Concentration | Biotechnology, Pharmaceuticals, Biotechnology & Life Sciences, Health Care, NASDAQ Composite, NASDAQ Health Care, Health Care, Biotechnology, Biotechnology, Healthcare (View all Sectors) | |||||||||||||||||||||||||||||||||||||||||||||
| Average Analyst Recommendation | ||||||||||||||||||||||||||||||||||||||||||||||
Financial Strength
| ||||||||||||||||||||||||||||||||||||||||||||||
Debt LevelsTranscode Therapeutics utilizes debt financing to potentially enhance returns on invested capital. The relationship between total debt and total assets provides valuable insight into Transcode Therapeutics' leverage profile, showing how much of Transcode Therapeutics' resources are funded through borrowing.
| ||||||||||||||||||||||||||||||||||||||||||||||
Transcode Therapeutics (RNAZ) is traded on NASDAQ Exchange in USA and employs 7 people. Transcode Therapeutics is listed under Biotechnology category by Fama And French industry classification. The company currently falls under 'Nano-Cap' category with a current market capitalization of 9.05 M. Transcode Therapeutics conducts business under Biotechnology sector and is part of Health Care industry. The entity has 916.97 K outstanding shares of which 113.88 K shares are at this time shorted by private and institutional investors with about 0.21 trading days to cover.
Transcode Therapeutics currently holds about 13.45 M in cash with (13.34 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 1.04.
Check Transcode Therapeutics Probability Of Bankruptcy
Ownership AllocationTranscode Therapeutics has 9.2 % of its outstanding shares held by insiders and 5.67 % owned by institutional holders.
Check Transcode Ownership Details
Transcode Stock Institutional Holders
| Instituion | Recorded On | Shares | |
| Drw Securities, Llc | 2025-09-30 | 11.7 K | |
| Ubs Group Ag | 2025-09-30 | 0.0 | |
| Citigroup Inc | 2025-09-30 | 1.6 K | |
| Tower Research Capital Llc | 2025-09-30 | 142 | |
| Sbi Securities Co Ltd | 2025-09-30 | 10.0 | |
| Royal Bank Of Canada | 2025-09-30 | 8.0 | |
| Bank Of America Corp | 2025-09-30 | 8.0 | |
| Advisor Group Holdings, Inc. | 2025-09-30 | 3.0 | |
| The Goldman Sachs Group Inc | 2025-09-30 | 0.0 | |
| Federation Des Caisses Desjardins Du Quebec | 2025-12-31 | 0.0 | |
| Fmr Inc | 2025-09-30 | 0.0 |
Transcode Therapeutics Historical Income Statement
Transcode Stock Against Markets
Transcode Therapeutics Corporate Management
| RN MBA | Senior Operations | Profile | |
| Daniel MD | Chief Officer | Profile | |
| Anna Moore | Scientific CoFounder | Profile | |
| Calais Pharm | Executive Board | Profile | |
| Robert Dudley | CEO, CoFounder | Profile |
Additional Tools for Transcode Stock Analysis
When running Transcode Therapeutics' price analysis, check to measure Transcode Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Transcode Therapeutics is operating at the current time. Most of Transcode Therapeutics' value examination focuses on studying past and present price action to predict the probability of Transcode Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Transcode Therapeutics' price. Additionally, you may evaluate how the addition of Transcode Therapeutics to your portfolios can decrease your overall portfolio volatility.